Introduction
The filarial parasites (Class: Nematoda; Superfamily: Filarioidea) include approximately 500 species infecting almost all vertebrates except fish. The parasites reside in lymphatics, connective tissues, or body cavities of the vertebrate hosts, and the infection is transmitted by a blood-sucking arthropod vector. The filarial species infecting only humans are: Wuchereria brancrofti, Brugia malayi, and B. timori, which are responsible for lymphatic filariasis (LF) causing debilitating disease manifestations such as "elephantiasis" and hydrocele, Onchocerca volvulus that causes "river blindness", and Loa loa causing "loiasis" ("calabar swelling"). Other prevalent but benign human filariids are: Acanthocheilonema perstans, Acanthocheilonema streptocerca, and Mansonella ozzardi, as well as the less frequent minor species: W. lewisi, B. beaveri, B. guyanensis, M. semiclarum, Dipetalonema arbuta, D. sprenti, Microfilaria bolivarensis, and M. rodhaini. LF is a major disease with ever increasing prevalence in the developing world and the second leading cause of permanent and long-term disability. Globally, about 1 billion people live in areas endemic to LF (80 countries) and thus are exposed to the risk of infection. About 120 million suffer from the infection or the chronic filarial disease manifestations such as edema of limbs, breast, external genitalia, or hydrocele [6] . It is estimated that medical treatment for acute and chronic LF manifestations costs millions of dollars each year across the endemic regions. In India alone over 10 million people per year seek treatment for LF, which accounts for a total of 30 million dollars per annum. It is thought that the measurable health care costs of treating LF are small in proportion to the individual and societal costs from lost productivity. The contribution of LF to tropical disease burden in terms of disability adjusted life years (DALY) -which basically indicates the amount of healthy life expectancy lost because of a disease or disability caused by it, or risk factor, including both mortality and morbidity -is around 5.94 million globally and over 2.62 million for India [7] . LF infection is spread by Anopheles, Culex, Aedes, and Mansonia species of mosquitoes. During a blood meal, the mosquito takes up the stage 1 larvae or microfilariae (mf) circulating in the blood of an infected human. In the mosquito, mf undergoes two molts to become stage 3 infective larvae (L 3 ) which enter the human host during a blood meal of the vector. L 3 penetrate through the local connective tissue and enter the lymphatic vessels [8] where they take 2 to 12 months to develop into adult worms through two molts. Mature male and female worms mate and produce the progeny, mf, which enter the bloodstream from where they are picked up by the mosquito during its blood meal, and the life cycle continues. Onchocerciasis is the second major filarial disease group and affects around 18 million people, mainly in tropical Africa and Latin America [9] . The infection is presented as a spectrum of dermal and ocular lesions resulting from the presence of microfilariae in the skin and eyes. The severity of the pathology which may cause blindness has attracted a massive international effort to reduce the impact of onchocerciasis through vector control and by mass chemotherapy [10] . Among non-filarial nematode infections, the soil-transmitted helminths (STH) commonly known as intestinal worms are the most common infections worldwide and constitute an important community health problem. The causal parasites are: Ascaris lumbricoides, Trichuris trichiura, and the hookworms Ancylostoma duodenale and Necator americanus. Recent estimates suggest that A. lumbricoides infects over 1 billion people, T. trichiura 795 million, and hookworms 740 million. The greatest numbers of STH infections occur in sub-Saharan Africa, the Americas, China, and East Asia [11] . STH affect most frequently children and produce diarrhea, abdominal pain, general malaise, and weakness that may affect working and learning capacities and impair physical growth and activity. Hookworms cause chronic intestinal blood loss leading to anemia [12] [13] [14] [15] [16] . A list of human helminth infections other than filariasis is given in l " Table 1 .
In vitro and in vivo Systems for Screening Potential Antifilarials ! Being multicellular advanced organisms displaying considerable host specificity, the helminth parasites pose several challenges in the development of convenient and reliable laboratory test systems for assaying plant and synthetic products for anthelmintic and antifilarial activity. In the case of the filarial parasite, there are two main challenges: first, there are 16 distinct human filarial parasite species and the efficacy of the products may show species specificity and parasite stage-specificity. For instance, a product may show about 80% efficacy against adult worms of Onchocerca spp. but only show an identical or acceptable activity against the larval microfilariae stage of B. malayi (unpublished observation). Consequently, to maximize the exploration, a given product, whether active or inactive against one parasite, has to be tested against life stages of multiple species. The second challenge is the availability, maintainability, and responses of some of the target parasites/parasite life stages in vitro and transmission of infection to nonhuman laboratory animal models. For example, the most prevalent lymphatic filariid, W. brancrofti, is seldom used for in vitro or in vivo screening. This is because the infection cannot be transmitted to or maintained in small laboratory animals. As a result we do not have a convenient screening model of this parasite and a source of the parasite life stages for in vitro use. However, our improved understanding in the recent decades of the biology and host parasite interactions helped us developing not only useful in vitro systems but also successful transmission of human infections into small and larger laboratory animals for in vivo screening [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . The different in vitro screen systems developed over the decades and employed for screening plant and synthetic products are given in l " Table 2 . The assays employ one or more life stages (L 3 , mf, or adult worms) of the parasite depending upon the feasibility or type of activity (larvicidal, microfilaricidal, or macrofilaricidal) desired. The endpoints used in the assays include inhibition (in the parasite) of: motility, reduction of a tetrazolium salt to its formazan, parasite specific glutathione-S-transferase, enzymes involved in antioxidant generation or free radical scavenging, molting of L 3 to L 4 , embryogenesis, and mf release from female worms. The assays are employed as prescreens either singly or as a battery of two or more assays and the most frequently used battery consists of motility assay and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) reduction assay. Using this battery, a product is considered active if it causes complete inhibition in motility and/or > 50 % inhibition in MTT reduction. The advantage of the assays are that a) a large number of products can be screened, b) they require a small amount of the test product for the assay, and c) the assays can be completed within 24-48 hrs [32, 33] . Investigators have also used 120 hr incubation in order not to miss products that act slowly [34] . The main disadvantage of the in vitro pre-screens is that they detect antifilarial activity of only those products which do not require metabolic activation to active pharmacophore. As a result several products that are negative in vitro but which may show activity after bitransformation in the host are missed. It is therefore necessary to include in the in vitro incubations a metabolic activation system such as the liver microsomal fraction (S9 mix) rich in most of the cytochrome P450 isoforms. An (expensive) alternative is testing all products, whether active or inactive in vitro, in suitable animal models of the infection. Although tests employing animal models are labor intensive, expensive, lengthy, and often difficult to scale-up, they are sufficiently reliable, and the conclusions drawn from them are frequently transferable to human infection, provided sufficient care is taken in the selection of the host-parasite system. Our understanding of the host-parasite interactions and immune responses of the host in human filariasis and in a variety of animal models of the human infection has greatly improved in recent years [20, [60] [61] [62] and as a result we now have well-characterized animal models for assaying antifilarial activity (l " Table 3 ).
Historically, attempts to transmit the human filarial infections to laboratory animals were unsuccessful. This necessitated the use of alternative animal models for antifilarial drug discovery programs. One of the earliest models is Litomosoides carinii infection in the cotton rat. Introduced in 1944 [63] , this was used as a primary screen and was instrumental in the discovery of the microfilaricide diethylcarbamazine (DEC). However a major drawback with this model was that the host can only be infected through the vector but not by manual injection of infective larvae. So, there is no way of knowing how many, if at all, infective larvae had been introduced into the host by the vector. This is important for reproducible 1) determination of the percent yield of adult worms (= % larvae surviving and developing in to adult worms), and 2) quantifying the macrofilaricidal and worm sterilizing effect of the test drug. Another model which was established in ʼ70s is Acanthocheilonema viteae in the jird (Meriones unguiculatus) and in Mastomys coucha. These models overcame the deficiencies of the L carinii/cotton rat model and were considered acceptable [64] as a surrogate primary screen for products against human O. volvulus infection. However, for a long time there was still no rodent model for human lymphatic filarial infections with W. bancrofti and B. malayi. The real breakthrough came with the successful transmission of B. malayi to the rodents jird [65, 66] and Mastomys coucha [18, 67, 68] and recently, to nonhuman primates [25, 29, 31, 69] . In M. coucha the infection is introduced by subcutaneous injection of a known number of L 3 . In jird, in addition to the s. c. route, the infection can also be initiated by intraperitoneal instillation of a known number of adult worms or L 3 . The latter method not only makes the animal microfilaremic in a short period but is especially useful for assaying macrofilaricidal efficacy of products by following the fate of instilled worms. Both the rodent models show high and sustained microfilaraemia for prolonged periods which is advantageous for assaying microfilaricides. An additional feature of the M. coucha is its susceptibility to develop filarial disease manifestations (unpublished observation). Among nonhuman primates, the leaf monkeys (Presbytis spp.) were found to be especially susceptible to B. malayi infection [25, 29] and among them the Indian leaf monkey displays responses similar to those shown by human subjects harboring the infection, including the recurrent febrile and limb edema episodes, hydrocoele, and eosinophilia [29] .
With the availability of adequate animal models of human filarial infection, the new product screening protocol has been revised by the WHO. At the authorsʼ Institute the protocol conducted is largely based on WHO recommendations and is as follows: Prescreen: In vitro motility and MTT assays using adult worms and mf of B. malayi for short-listing. This is followed by IC 50 (the concentration at which the parasite motility is inhibited by 50 %) determination using the same assays and CC 50 (cytotoxic concentration at which 50 % of cells are killed) determination using VERO Cell line C1008 (African green monkey kidney cells) [33, [89] [90] [91] . 
In vitro (primary) screens
For screening potential synthetic or plant derived anthelmintics (other than antifilarials) several nematode, cestode, and trematode parasites have been used in in vitro systems (l " Table 4 ). The selection of parasites for the in vitro systems is apparently based on considerations such as easy availability, adaptability to laboratory conditions, ease in handling, and, when the human parasite cannot be used, the similarities between human and surrogate parasite responses to known drugs and/or taxonomical proximity of the species chosen. This approach would appear justified by several instances of intergeneric chemotherapeutic responses within the same family. Among nematodes, such a relationship is known to exist between murine oxyurid and Enterobius vermicularis with piperazine; between Nippostrongylis muris and trichostrongyles of sheep and cattle or hookworms of man and dog with bephenium and between Strongyloides ratti and S. stercolaris with dithiazanine [92] .
In vivo Tables 5 and 6 show a list of animal models for primary and secondary screening, respectively. The in vivo primary and secondary screening would strengthen the results obtained in the in vitro prescreening. The in vivo screens will also demonstrate whether the spectrum of activities can be extended to the related parasites in different hosts and to efficacy in human subjects. Parasites having a short and direct life cycle needing no vector would obviously need less time and labor and would be economical to generate results. Hymenolepsis nana, a human tapeworm, in natural condition, is cycled through intermediate host (Tribolium confusum) but also attains maturity in one and the same host within 15 days of incubation of eggs. This system will also facilitate the assessment of drugs against cysticercoides and adult worms in the same infected animal. Small hosts with minimum genetic variations and easily available in adequate numbers are usually preferred for reproducibility.
Inspite of all the care exercised in selecting the best host-parasite system, the results obtained in experimental hosts can not totally be translated to the target parasite in its natural host because the different compounds behave differently in different hosts (absorption, kinetics, resorption and distribution, etc.) [104] . This might be crucial for decision making regarding whether or not it should enter successive steps of drug development program. The different in vitro and in vivo systems, their utility and drawbacks have been recently reviewed by Keiser [101] .
Plants for Filariasis

!
In modern medicine the drugs used for lymphatic filariasis are diethylcarbamazine (DEC) [70] and ivermectin [105] , and a singledose treatment with DEC or ivermectin, or combination of DEC or ivermectin with albendazole is currently employed in an attempt to control the infection. DEC and ivermectin are microfilaricides and therefore only useful in reducing transmission and pathology. New drugs are required to improve treatment by killing the adult worms (macrofilariae), which are long-lived, and to replace the currently used drugs before drug resistance starts appearing [106] . In the last few decades a lot of emphasis has been laid on the development of antifilarial agents from plant or natural products by many investigators [32, 48, 82, 107, 108] and to develop traditional plant-based medical preparations incomplementary or alternative medicines (CAM) supported by scientific validation of efficacy and safety and quality control of the preparations. Although there are few specific reports on the antifilarial properties of plant extracts or products, it is not unusual to find these indications cited amongst a general list of medicinal plants [109, 110] . Some plants are reported to be active against tissue dwelling nematodes and various filarial species and are used in traditional systems of medicine [111] . l " Table 7 shows a list of plants studied for activity against filarial parasites [112] . Some of these are tested for their antifilarial activity mostly in vitro and some in vivo. Among these, Streblus asper, a plant used in traditional medicine for lymphedema, is the only plant that has been studied extensively and systematically in vitro as well as in vivo and whose active constituents were chemically characterized. A preparation of plant decoction named "filacid" made from the stem bark of S. asper has been administered to over 5000 filarial patients at a filaria clinic in Varanasi, India, during the period 1970-1987 [113, 114] and was found to be effective in the treatment of filarial lymphedema, filarial chyluria, and other conditions of the disease. In comparative trials, other plants used in traditional medicine were found to be less effective (viz. Crataeva nurvala
than "filacid" in the treatment of filarial lymphedema [112, 113] . Later, the stem bark extract was found to be active against several filarial species including B. malayi in vitro and in vivo. The active principles were identified as two cardiac glycosides, asperoside and strebloside [107] . For onchocerciasis, there are relatively fewer reports of plant-based traditional medicine in the literature. Aloe barteri was cited for the treatment of O. volvulus-induced skin conditions [109] . Another plant, Cassia aubrevellei, which is believed in Liberia to be useful in skin conditions associated with onchocerciasis, was found to be inactive against female parasites recovered from nodules of patients [115] . On the contrary, the plant extract increased the density of skin microfilariae [116] . Extracts of some Cameroonian plants like Carapa procera, Pachypodanthium staudth, and Polyalthia sauveolens were also found to be effective against filarial parasites. The active principles of these plants were identified as carapolide A and oliverine and were tested against O. volvulus in vitro by Titanji et al. [117] . Cardol, a phenolic compound isolated from Anacardium occidentale is reported to be active against bovine filariid S. cervi in vitro [118] . Other in vitro/in vivo investigations of plant extracts have also been reported against various filarial species [116, [119] [120] [121] [122] [123] . Both aqueous and alcoholic extracts of the leaves of Mallotus philippensis and Sencio nudicaulis were effective in inhibiting the movements of the nerve-muscle (n. m.) preparation of S. cervi. The stimulatory response of acetylcholine was blocked by the aqueous extract on whole worm movements [124] . The effect of S. nudicaulis extracts was different from that produced by the calcium channel blocker nifedipine on the whole worm and n. m. preparation. While nifedipine blocks the stimulant effect of Ach, the extract of S. nudicaulis fails to do so. This response bears similarity with DEC, which also does not block AchE response. However, interpretation of these activities in terms of target filarial infections in vivo is difficult. The majority of the filaricidal applications of plant products reported in the early literature are for the treatment of guinea worm (Dracunculus sp.) which was earlier considered as a filarial parasite but is now included in a separate group. Plant extracts are in many cases applied externally to the sore caused by guinea worm indicating that most of the observed effects may be due to direct topical effect of the agent on the parasite or wound. Several plant products were also reported active when given orally. Root decoction of Combretum micranathum was reported to help in expelling guinea worms in infested patients; inflammation around the lesions was also reduced [125] . The leaves of Elaeophorbia drupifera and Hilleria latifolia taken in combination with a palm soup preparation were found to be guinea wormicidal [125] . In laboratory investigations several plant products were identified with antifilarial activity. In vitro, macrofilaricidal activity was shown by ethanolic and aqueous extracts of the medicinal plant Cardiospermum halicacabum against B. pahangi in terms of reduced motility of both male and female adult worms and reduced microfilarial release and motility (ethanolic extract) [126] . Methanolic extracts of the root of Vitex negundo L. (containing alkaloids, saponin, and flavonoids) and leaves of Aegle marmelos Corr. (containing coumarins) produced complete loss of motility of microfilariae of B. malayi [127] . Extracts of Butea monosperma leaves and roots showed significant inhibition of motility in a dose-dependent manner of B. malayi microfilariae [32] . In animal models, crude extract and hexane fraction of marine red alga Botryocladia leptopoda killed adult filarial parasites of L. sigmodontis and A. viteae and caused sterilization of B. malayi female worms [128] . Crude extract and chloroform fraction of the stem portion of the plant Lantana camara showed adulticidal and female worm sterilizing activity against B. malayi in M. coucha and in jirds with i. p. instilled B. malayi adult worms. Oleanonic and oleanolic acids isolated from the hexane and chloroform fractions showed considerable antifilarial activity on B. malayi in vitro. Inhibition of motility and subsequent mortality of adult worms of S. digitata was produced in vitro by extracts of Cedrus deodara, Ricinus communis, Sphaeranthus indicus, and Centratherum anthelminticum in decreasing order [54] . Crude extract (and an active fraction of it) of Trachyspermum ammi fruit inhibited motility and killed S. digitata worms in vitro and showed macrofilaricidal and female sterilizing efficacy in vivo against B. malayi in M. coucha. The active compound was isolated and found to be a phenolic monoterpene [129] . Potential microand macrofilaricidal efficacy against B. pahangi was shown by ethanol extract of leaves of Neurolaena lobata, a Guatemalan medicinal plant [58] . Aqueous, butanol, and hexane extracts of Caesalpinia bonducella-seed kernel demonstrated microfilaricidal, macrofilaricidal, and female-sterilizing efficacy against L. sigmodontis in cotton rats and microfilaricidal activity against B. malayi in M. coucha [130] .
Plants for Helminthiasis (Other Than Filariasis)
!
The literature concerning the use of plants as anthelmintics (l " Table 8 ) is more extensive [158, 159] and preparations from many of these plants are in current use. With few exceptions, e.g. the investigation by Kiuchi et al. [111] on tissue dwelling nematodes, the majority of them are effective against intestinal helminths. The most widely known and investigated anthelmintics of plant origin are ascaridole, derived from Chenopodium ambrosoides [158] and the phloroglucinols aspidin and deaspidin, from the male fern Dryopteris filix mas. They are used effectively to treat tapeworm infections [160] . Some of the plant [109, 150] continued next page products are vermicides while others are vermifuges. Oil of chenopodium (ascaridole) is effective against Ascaris and hookworms but is highly toxic. Aspidum is one of the oldest used anthelmintics obtained from the rhizomes of the fern Dryopteris filix mass. Polyhydric phenol is its active principle (filicic acid and filicin). The product has specific action against intestinal cestodes: Diphyllobothrium, Taenias, Hymenolepis spp and others, and acts probably by paralyzing the muscles of parasites. However, the drug is toxic and causes polyneuritis and paralysis of the iris. Santonin is the oil obtained from the seeds of Artemisia maritima. Flowering tops of this plant were used by physicians of Greece as early as 60 AD. The decoction of the stem bark of Zanthoxylum liebmannianum decreased the count of intestinal nematode eggs in naturally infected sheep while the chloroform extract was found to be toxic to Ascaris suum. Alpha-sanshool from Z. liebmannianum was found to be the active compound. However, alpha-sanshool induced tonic-clonic seizures in mice and thus has some toxicity [161] . Thymol obtained from Thymus vulgaris is a monohydric phenol (methyl isopropyl phenol) and is used as vermicide in eliminating hookworms and Trichinella spiralis. Thymol is not active against Ascaris, Trichuris, and Enterobius. It is neurotoxic and affects kidneys. Pelletierin is an alkaloid obtained from the pomegranate tree, Punica granatum, and is active against Taenia sp. but causes headache, dizziness, nausea, vomiting, and diarrhea with colic pain; it is also known to be neurotoxic. Arecanut, the seed of Areca catechu is also known for its anthelmintic action; its active principle is arecoline, a colorless liquid. Dried flowers of Hagenia abyssnica, commonly called as "Kousso" or Cusso, are used against tapeworm (Taenia sp.) infections. Their active principle is identified as kosatxin. Palasonin derived from Butea frondosa and its piperavine salts were found to be active against A. lumbricoides [162] . Although these are not advantageous over existing synthetic anthelmintics (benzimidazole derivatives and ivermectin), they are effective in expelling the worms if used as a purgative. Interestingly, some plant anthelmintics directly inhibit the wormsʼ motility due to cholinergic agonist/antagonist action as in the case of arecolin. However, the action of all these agents depends on several host factors too. [163] . The latex of some species of Ficus (Moraceae) has been traditionally used as vermifuge in Central and South America. However, due to high acute toxicity (hemorrhagic enteritis), lateces are not recommended for use in traditional medicine [164] . Extract of the dried fruits/crushed seeds of Embelia schimperi Vatke, belonging to the family Myrsinaceae, is used by the Masai people of Tanzania and Kenya who believe that it eliminates adult Taenia saginata, the beef tapeworm. It was effective against tapeworms Hymenolepis diminuta in a rat model. No significant in vivo effect was observed against H. microstoma, the trematode Echinostoma caproni, and the nematode Heligmosomoides polygyrus in mice, although the worms could be killed in vitro. These results indicate that the crushed seeds of E. schimperi taken orally by the Masai people, indeed have an anthelmintic activity against human intestinal tapeworms [165] . The West African legume Millettia thonnigii is used in Ghana as an anthelmintic and as a purgative [166] . A chloroform extract of the seeds of Millettia thonningii which is known to be molluscicidal and cercaricidal was topically applied to mouse skin 2 and 24 hours prior to exposure to S. mansoni cercariae. The presence of M. thonningii extract components on the surface of the skin appeared to be effective in preventing subsequent establishment of infection. The compound responsible for the activity is thought to be the isoflavonoid alpinumisoflavone. The aqueous extract of Albizzia anthelmintica bark showed high anthelmintic activity (68-100%) against experimental H. diminuta infection in albino rats; it was not toxic. The water extract from A. lebbek bark was less effective against the cestode and was toxic to rats at a high dose [167] . Papaya latex (Carica papaya) showed an antiparasitic efficacy against Heligmosomoides polygyrus in a mice model [168] . Sainfoin (Onobrychis viciifolia) extracts containing condensed tannins inhibited the migration of 3rd-stage larvae of Haemonchus contortus [169] . 5,7-Dihydroxyflavanone (pinocembrine) from the acetone extract of Teloxys graveolens (Willd.) Weber (Chenopodiaceae) exhibited fasciolicide, ovicide, and larvicide activities on newly excysted Fasciola hepatica, on infective eggs of A. galli, and on stage 3 larvae of Stomoxys calcitrans, respectively [170] . One of the flavones from Struthiola argentea (Thymelaeaceae) identified as 5,6,2′,5′,6′-pentamethoxy-3′,4′-methylenedioxyflavone, demonstrated the most potent anthelmintic activity with 90 % inhibition of larval motility in vitro [171] . The crude aqueous and hydro-alcoholic extracts of the seeds of Coriandrum sativum (Apiaceae) inhibited hatching of eggs of H. contortus completely in a dose-dependent manner. The hydro-alcoholic extract showed better in vitro activity against adult parasites than the aqueous one [172] .
Conclusions and Prospects
!
From times immemorial, the plant kingdom has been a veritable source of medicinal agents, and there are several success stories of plant derived drugs even in modern medicine. However, our efforts to discover plant products or develop new drugs on plant-based leads for the control and treatment of filariasis and other helminth infections have not been met with much success. In the last five decades, more than 100 plant products were reported to be beneficial in the treatment or control of these parasitic infections but they could not be developed into viable drugs for a variety of reasons. New animal models of human infection developed in recent years improved our understanding of host parasite interactions and provided us better models to identify anthelmintic/antifilarial activity of plant products. It is expected that the newer assay batteries coupled with quality controlled systematic plant identification, collection, storage, processing, etc., and the state-of-the-art technology of chemical "fingerprinting" of the products would help us build some success stories in the area of filariasis/helminth infections.
